Loading
The 2020 European LeukemiaNet recommendations set the response milestones for kinase inhibitor therapy in chronic myeloid leukaemia, when to switch drugs, and how to manage accelerated and blast phase, including transplant.
Consensus recommendations covering diagnosis, risk scoring (ELTS), first-line and later-line tyrosine kinase inhibitors, molecular response milestones, treatment-free remission, and the management of advanced-phase disease with kinase inhibitors, chemotherapy and allogeneic transplantation.
Whether a patient is on track at three, six and twelve months, and when a change of drug or a transplant referral is warranted, is judged against these milestones.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/